Get the Stockscreener App
0.6011
3.70%
-0.0231
Renalytix Plc ADR stock is currently priced at $0.6011, with a 24-hour trading volume of 377.67K.
It has seen a -3.70% decreased in the last 24 hours and a -31.97% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.6281 pivot point. If it approaches the $0.5962 support level, significant changes may occur.
Previous Close:
$0.6242
Open:
$0.669
24h Volume:
377.67K
Market Cap:
$38.00M
Revenue:
$2.41M
Net Income/Loss:
$-42.50M
P/E Ratio:
-0.5465
EPS:
-1.1
Net Cash Flow:
$-36.15M
1W Performance:
-25.05%
1M Performance:
-31.97%
6M Performance:
-45.35%
1Y Performance:
-74.42%
1D Range:
$0.5962
$0.669
52W Range:
$0.2449
$4.0377
Renalytix Plc ADR Stock (RNLX) Company Profile
Name
Renalytix Plc ADR
Sector
Industry
Phone
44 20 3139 2910
Address
Avon House, 19 Stanwell Road Penarth, Cardiff
Renalytix Plc ADR Stock (RNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-18-22 | Initiated | H.C. Wainwright | Buy |
| Jan-04-22 | Initiated | BTIG Research | Buy |
| Oct-04-21 | Initiated | Guggenheim | Buy |
| Jul-02-21 | Initiated | Berenberg | Buy |
| Aug-11-20 | Initiated | Stifel | Buy |
Renalytix Plc ADR Stock (RNLX) Latest News
Renalytix Announces Financing with Expected Size of up to $4 Million
GlobeNewswire Inc.
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
GlobeNewswire Inc.
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Benzinga
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why Paymentus Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Benzinga
Renalytix Plc ADR Stock (RNLX) Financials Data
Renalytix Plc ADR (RNLX) Revenue 2024
RNLX reported a revenue (TTM) of $2.41 million for the quarter ending December 31, 2023, a -36.65% decline year-over-year.
Renalytix Plc ADR (RNLX) Net Income 2024
RNLX net income (TTM) was -$42.50 million for the quarter ending December 31, 2023, a -0.59% decrease year-over-year.
Renalytix Plc ADR (RNLX) Cash Flow 2024
RNLX recorded a free cash flow (TTM) of -$36.15 million for the quarter ending December 31, 2023, a +0.87% increase year-over-year.
Renalytix Plc ADR (RNLX) Earnings per Share 2024
RNLX earnings per share (TTM) was -$0.90 for the quarter ending December 31, 2023, a +26.23% growth year-over-year.
About Renalytix Plc ADR
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform, which employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.
2.61%
0.37%
Cap:
|
Volume (24h):